FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896583947> ?p ?o ?g. }

• W2896583947 endingPage "92" @default.
• W2896583947 startingPage "54" @default.
• W2896583947 abstract "A considerable portion of the adult population has received and/or is receiving treatment with antiresorptive drugs (ARDs). It is thus relevant to assess possible side effects of ARD intake in connection to various aspects of implant therapy. The aim of this study was to answer the focused question In patients with systemic intake of ARDs, what is the outcome and complication rate of implant therapy including associated bone grafting procedures comparing to patients without systemic intake of ARDs?Original studies fulfilled predefined inclusion criteria (e.g., case series, cohort studies, case-control studies, and controlled and/or randomized controlled clinical trials; retro- or prospective design; and ≥10 patients with systemic intake of ARDs). Various patient-, medication-, and intervention-related parameters [i.e., implant loss, grafting procedure complication/failure, peri-implant marginal bone levels/loss, medication-related osteonecrosis of the jaws (MRONJ), and peri-implantitis] were extracted, and meta-analyses and quality assessment were performed.Twenty-four studies with bisphosphonate (BP) intake (mainly low dose for osteoporosis treatment) and seven studies on hormone replacement therapy (HRT), including ≥10 patients, and controls not taking the medication were identified. Furthermore, seven studies on MRONJ associated with implants were included. Meta-analyses based on four studies reporting on patient level and eight studies reporting on implant level showed no significant differences in terms of implant loss between patients on BPs (mainly low dose for osteoporosis treatment) and controls. Furthermore, low-dose BP intake did not compromise peri-implant marginal bone levels. Based on two studies, no negative effect of HRT was observed on the implant level, while HRT appeared to exert a marginally significant negative effect regarding implant survival on the patient level and regarding peri-implant marginal bone levels. Based on six studies reporting single-patient data, MRONJ in patients on BP for osteoporosis appeared in 70% of the cases >36 months after start of drug intake, while in patients with cancer, MRONJ appeared in 64% of the cases ≤36 months after first BP intake.Low-dose oral BP intake for osteoporosis treatment, in general, does not compromise implant therapy, that is, patients on ARDs do not lose more implants nor get more implant-related complications/failures comparing to implant patients without BP intake. There is almost no information available on the possible effect on implant therapy of high-dose BPs or other widely used ARDs (e.g., denosumab), or on the success or safety of bone grafting procedures. Patients with high-dose ARD intake for management of malignancies, patients on oral BP over a longer period of time, and patients with comorbidities should be considered as high-risk patients for MRONJ." @default.
• W2896583947 created "2018-10-26" @default.
• W2896583947 creator A5013781363 @default.
• W2896583947 creator A5025576392 @default.
• W2896583947 creator A5032153008 @default.
• W2896583947 creator A5066324718 @default.
• W2896583947 creator A5066448929 @default.
• W2896583947 creator A5075558627 @default.
• W2896583947 date "2018-10-01" @default.
• W2896583947 modified "2023-10-17" @default.
• W2896583947 title "The effect of antiresorptive drugs on implant therapy: Systematic review and meta-analysis" @default.
• W2896583947 cites W1520230219 @default.
• W2896583947 cites W1556094611 @default.
• W2896583947 cites W1859459673 @default.
• W2896583947 cites W1901003126 @default.
• W2896583947 cites W1969943645 @default.
• W2896583947 cites W1972332188 @default.
• W2896583947 cites W1972850638 @default.
• W2896583947 cites W1975259661 @default.
• W2896583947 cites W1975739920 @default.
• W2896583947 cites W1977350740 @default.
• W2896583947 cites W1977883531 @default.
• W2896583947 cites W1986393559 @default.
• W2896583947 cites W1989627049 @default.
• W2896583947 cites W1997823019 @default.
• W2896583947 cites W2003142365 @default.
• W2896583947 cites W2011184473 @default.
• W2896583947 cites W2015700744 @default.
• W2896583947 cites W2020880213 @default.
• W2896583947 cites W2024530615 @default.
• W2896583947 cites W2025440296 @default.
• W2896583947 cites W2029067598 @default.
• W2896583947 cites W2037607941 @default.
• W2896583947 cites W2043018502 @default.
• W2896583947 cites W2048644004 @default.
• W2896583947 cites W2057810779 @default.
• W2896583947 cites W2058889454 @default.
• W2896583947 cites W2060963812 @default.
• W2896583947 cites W2070222381 @default.
• W2896583947 cites W2071321718 @default.
• W2896583947 cites W2077088010 @default.
• W2896583947 cites W2077937093 @default.
• W2896583947 cites W2082068005 @default.
• W2896583947 cites W2083854248 @default.
• W2896583947 cites W2092815312 @default.
• W2896583947 cites W2107177524 @default.
• W2896583947 cites W2107549391 @default.
• W2896583947 cites W2113698406 @default.
• W2896583947 cites W2129334747 @default.
• W2896583947 cites W2144920566 @default.
• W2896583947 cites W2146820344 @default.
• W2896583947 cites W2152908925 @default.
• W2896583947 cites W2154182011 @default.
• W2896583947 cites W2155611642 @default.
• W2896583947 cites W2157956984 @default.
• W2896583947 cites W2169512870 @default.
• W2896583947 cites W2263286648 @default.
• W2896583947 cites W2274443098 @default.
• W2896583947 cites W2327271898 @default.
• W2896583947 cites W2341628337 @default.
• W2896583947 cites W234587587 @default.
• W2896583947 cites W2506644036 @default.
• W2896583947 cites W2518553496 @default.
• W2896583947 cites W2527811116 @default.
• W2896583947 cites W2576440140 @default.
• W2896583947 cites W2599879790 @default.
• W2896583947 cites W2612756049 @default.
• W2896583947 cites W2620769587 @default.
• W2896583947 cites W2742855816 @default.
• W2896583947 cites W2750703303 @default.
• W2896583947 cites W2775638715 @default.
• W2896583947 cites W321510085 @default.
• W2896583947 cites W4294215472 @default.
• W2896583947 doi "https://doi.org/10.1111/clr.13282" @default.
• W2896583947 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30306695" @default.
• W2896583947 hasPublicationYear "2018" @default.
• W2896583947 type Work @default.
• W2896583947 sameAs 2896583947 @default.
• W2896583947 citedByCount "65" @default.
• W2896583947 countsByYear W28965839472018 @default.
• W2896583947 countsByYear W28965839472019 @default.
• W2896583947 countsByYear W28965839472020 @default.
• W2896583947 countsByYear W28965839472021 @default.
• W2896583947 countsByYear W28965839472022 @default.
• W2896583947 countsByYear W28965839472023 @default.
• W2896583947 crossrefType "journal-article" @default.
• W2896583947 hasAuthorship W2896583947A5013781363 @default.
• W2896583947 hasAuthorship W2896583947A5025576392 @default.
• W2896583947 hasAuthorship W2896583947A5032153008 @default.
• W2896583947 hasAuthorship W2896583947A5066324718 @default.
• W2896583947 hasAuthorship W2896583947A5066448929 @default.
• W2896583947 hasAuthorship W2896583947A5075558627 @default.
• W2896583947 hasBestOaLocation W28965839471 @default.
• W2896583947 hasConcept C126322002 @default.
• W2896583947 hasConcept C141071460 @default.
• W2896583947 hasConcept C168563851 @default.
• W2896583947 hasConcept C188816634 @default.
• W2896583947 hasConcept C2776348555 @default.

• next